NCT07214584Recruiting
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase chain reaction (PCR; NavDx) and the other on branched DNA (Quantivirus HPV \[DNA\]). A 9-month feasibility study will be performed to examine the side-by-side utility of both NavDx and Quantivirus HPV DNA assays in predicting cervical cancer treatment response. These tests could prove to be highly sensitive methods for evaluating minimal residual disease and for quantitation of response to surgery, radiation, and chemotherapy in patients with cervical cancer. Primary Goal: Feasibility for NavDx HPV DNA assay (Naveris, Inc) to be used for personalized prediction of tumor response before and after treatment. Secondary Goals: 1. Comparability of the Quantivirus HPV DNA/mRNA assay (DiaCarta, Inc) with the NavDx HPV DNA assay and, 2. Feasibility of the Quantivirus technology for measuring treatment response within the first day to 2 weeks of radiation, surgery, or a new chemotherapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 7 Oct 2025
- Start date
- 15 Dec 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- University of Florida
- Diseases
- Cervical cancer
- NCT number
- NCT07214584
What you commit to
- Study type: Observational
- Planned participants: 55
- From 15 Dec 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosed with a synchronous malignancy requiring cancer-directed therapy
Other
- Unable to consent or refusal to sign a consent form
- Not meet any inclusion criteria
- Unable to comply with follow up scheduling.
Who the study is looking for
- 18 years and older
- HPV-associated squamous cell, adenocarcinoma, or adenosquamous cancers of the uterine cervix with evaluable disease
- Diagnosed with American Joint Committee on Cancer (AJCC) stage I or higher, or metastatic disease.
- Presence of evaluable disease on pre-treatment standard of care imaging with plans to obtain serial post-treatment standard of care imaging
- Agree to perform the required research-related blood tests and cervical mucous testing.
Age in the registry: 18 years to 89 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Florida Coordinator of this site? Confirm its status | Gainesville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.